title: The role of lonidamine in the treatment of breast cancer patients.
authors.affiliation: Divisione di Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Rosso
authors.forename: G
authors.initials: G
authors.lastname: Gardin
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: A
authors.initials: A
authors.lastname: Camoriano
authors.forename: L
authors.initials: L
authors.lastname: Merlini
authors.forename: C
authors.initials: C
authors.lastname: Naso
authors.forename: M
authors.initials: M
authors.lastname: Rosso
authors.forename: C
authors.initials: C
authors.lastname: Barone
authors.forename: O
authors.initials: O
authors.lastname: Nascimben
authors.forename: G
authors.initials: G
authors.lastname: Ianniello
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity*; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D015251:Epirubicin; D003520:Cyclophosphamide; C016371:lonidamine